ArticleBritish journal of haematology2026
Frailty and health resource utilization in 5450 adults with acute myeloid leukaemia: A population-based study from Ontario, Canada.
Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Frailty is a recognized prognostic factor in acute myeloid leukaemia (AML), yet its independent impact on healthcare resource utilization remains understudied. This study evaluated frailty's association with healthcare resource utilization (HRU) burden during the first year of AML treatment. We conducted a population-based retrospective cohort study using linked administrative databases in Ontario, Canada, involving 5450 AML adults (2006-2023) initiating chemotherapy. Frailty was assessed via a validated deficit-accumulation index. HRU outcomes-total-length of stay (LOS), intensive care unit (ICU)-LOS and hospital/emergency department (ED) visits-were measured as rates per person-year and their association with frailty measured as rate ratio (RR) using multivariable negative binomial regression, adjusting for age, sex and chemotherapy intensity. Frailty was independently associated with significantly higher HRU intensity. Compared to fit patients, frail patients demonstrated increased rates of total-LOS (RR 1.18), hospital/ED visits (RR 1.12) and, notably, ICU-LOS (RR 1.81). Conversely, advanced chronological age (≥65 years) correlated with lower ICU utilization (RR 0.60), suggesting critical care decisions may be more age-driven than based on physiological reserve. Frailty is a driver of HRU in AML, superiorly predicting high-acuity resource needs compared to chronological age. Routine frailty assessments are essential to inform resource allocation, guide treatment intensity, mitigate triage bias and improve value-based care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.